A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination with Low-Dose Dexamethasone versus High-Dose Dexamethasone in Subjects with Refractory or Relapsed and Refractory Multiple Myeloma

Trial Profile

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination with Low-Dose Dexamethasone versus High-Dose Dexamethasone in Subjects with Refractory or Relapsed and Refractory Multiple Myeloma

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Pomalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms NIMBUS
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 25 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 25 Jul 2017 Planned End Date changed from 1 Sep 2017 to 27 Aug 2017.
    • 04 Dec 2016 Results published in an Acetylon Pharmaceuticals Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top